Tuesday, March 04, 2025 | 07:12 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Biocon Revenues

Syngene International Q3 results: PAT rises 17.6%, revenue up 10.6%

During the quarter, Discovery Services launched "China+1" pilots with large and mid-size pharma companies and converted them into long-term contracts. Growth signals stabilizing

Syngene International Q3 results: PAT rises 17.6%, revenue up 10.6%
Updated On : 24 Jan 2025 | 12:10 PM IST

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

Biocon considers selling generic API biz; turn into biosimilar major
Updated On : 15 Dec 2023 | 1:09 PM IST

Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

The opportunity ahead of us is massive because over the next 10 odd years until 2032, we see 55 blockbuster molecules and biologics going out or losing exclusivity, says Tambe

Biocon Biologics targets top three biosimilar spot: Shreehas Tambe
Updated On : 13 Nov 2023 | 9:46 PM IST

Biocon Q2 results: Net profit zooms over two-fold to Rs 173 crore

Biotechnology major Biocon on Friday said its consolidated net profit rose an over two-fold to Rs 173 crore for the second quarter ended September 30, 2023. The company had reported a net profit of Rs 82 crore for the July-September period of the last fiscal. Total income rose to Rs 3,620 crore for the second quarter as against Rs 2,384 crore in the year-ago period, Biocon Ltd said in a regulatory filing. Shares of the company on Friday ended 0.11 per cent higher at Rs 227.35 apiece on the BSE.

Biocon Q2 results: Net profit zooms over two-fold to Rs 173 crore
Updated On : 10 Nov 2023 | 5:34 PM IST

Biocon Biologics gets positive opinion from EMA for ophthalmology product

Yesafili aims to treat various visual impairments and age-related macular degeneration

Biocon Biologics gets positive opinion from EMA for ophthalmology product
Updated On : 24 Jul 2023 | 1:58 PM IST

Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%
Updated On : 14 Nov 2022 | 10:13 PM IST

Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21

Analysts estimate 38 per cent annual growth in earnings during FY20-22

Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21
Updated On : 22 May 2020 | 1:37 AM IST

Top headlines: Biz sentiment sinks to record low, Moody's outlook on banks

Business Standard brings to you the top headlines of the day

Top headlines: Biz sentiment sinks to record low, Moody's outlook on banks
Updated On : 02 Apr 2020 | 4:37 PM IST

Biocon targets $1 bn in revenues by FY19 with new products and services

The Bengaluru-based firm has been chasing the target since 2011

Image
Updated On : 10 Sep 2017 | 11:00 AM IST